SMAD3 and pulmonary arterial hypertension: Surprisingly, anti-Activin A antibody had no significant effect on their canonical downstream targets, Smad2 and Smad3, and did not modulate Smad1/5 phosphorylation in either PAH or control PAVSMC, as shown in Figure 4, suggesting that other mechanisms are involved.